ProJect Pharmaceutics

Executive Summary

ProJect Pharmaceutics GmbH is a German CDMO specializing in advanced formulation and process development for complex parenteral drugs, including proteins, peptides, ADCs, cytotoxics, and live virus vaccines. Founded in 2010 and based in Martinsried, the company leverages Quality-by-Design principles for lyophilization cycle development and non-GMP pilot batch manufacturing for preclinical supply. As a private, pre-clinical stage contract organization, ProJect Pharmaceutics supports biotech and pharma clients in transforming challenging drug candidates into stable, deliverable products. The company's expertise in handling diverse modalities positions it well in the growing CDMO market, though its limited scale and lack of disclosed financials suggest a niche rather than market-leading position. Key strengths include deep technical know-how in lyophilization and formulation, while risks include reliance on client projects and competition from larger CDMOs.

Upcoming Catalysts (preview)

• Q3 2026New Client Contracts for ADC Formulation65% success
• Q4 2026Capacity Expansion for Lyophilization Services40% success
• Q1 2027Partnership with Live Virus Vaccine Developer30% success